Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment;Hémolyse post transfusionnelle du patient drépanocytaire : prévention, diagnostic, traitement

Transfusion Clinique et Biologique

Volumn 24, Issue 3, 2017, Pages 227-231

  Pirenne, F ^a,b   Bartolucci, P ^b,c   Habibi, A ^b,c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Allo immunisation; Hemolysis; Sickle cell disease; Transfusion

Indexed keywords

ECULIZUMAB; ERYTHROPOIETIN; IMMUNOGLOBULIN; STEROID; ALLOANTIBODY; CORTICOSTEROID; MONOCLONAL ANTIBODY; RITUXIMAB;

ATTITUDE TO HEALTH; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; HUMAN; PROPHYLAXIS; RISK FACTOR; SHORT SURVEY; SICKLE CELL ANEMIA; THERAPY DELAY; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; BLOOD; BLOOD GROUP TYPING; IMMUNIZATION; IMMUNOLOGY;

ADRENAL CORTEX HORMONES; ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD GROUPING AND CROSSMATCHING; HUMANS; IMMUNIZATION; ISOANTIBODIES; RITUXIMAB; TRANSFUSION REACTION;

EID: 85021385750     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2017.05.016     Document Type: Short Survey

References (25)

1. Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339 (1998), 5–11.
2. Cohen, A.R., Martin, M.B., Silber, J.H., Kim, H.C., Ohene-Frempong, K., Schwartz, E., A modified transfusion program for prevention of stroke in sickle cell. Blood 79 (1992), 1657–1661.
3. Habibi, A., Arlet, J.B., Stankovic, K., Gellen-Dautremer, J., Ribeil, J.A., Bartolucci, P., et al. French guidelines for the management of adult sickle cell disease: 2015 update. Rev Med Interne, 36, 2015 [5S3-5S84].
4. Vidler, J.B., Gardner, K., Amenyah, K., Mijovic, A., Thein, S.L., Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol 169 (2015), 746–753.
5. Win, N., New, H., Lee, E., de la Fuente, J., Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 48 (2008), 1231–1238.
6. King, K.E., Shirey, R.S., Lankiewicz, M.W., Young-Ramsaran, J., Ness, P.M., Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells. Transfusion 37 (1997), 376–381.
7. Habibi, A., Mekontso-dessap, A., Guillaud, C., Michel, M., Razazi, K., Khellaf, M., et al. Delayed hemolytic transfusion reaction in adult sickle cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol 91 (2016), 989–994.
8. Chou, S.T., Jackson, T., Vege, S., et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 122 (2013), 1062–1071.
9. Silvy, M., Tournamille, C., Babinet, J., Pakdaman, S., Cohen, S., Chiaroni, J., et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica 99 (2014), e115–e117.
10. Meunier, N., Rodet, M., Bonin, P., Chadebech, P., Chami, B., Lee, K., et al. Study of 206 transfused sickle cell disease patients: immunization, transfusion safety and red blood cell supply. Transfus Clin Biol 15 (2008), 377–382.
11. Sins, J.W., Biemond, B.J., van den Bersselaar, S.M., Heijboer, H., Rijneveld, A.W., Cnossen, M.H., et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol 91 (2016), 763–769.
12. Fasano, R.M., Booth, G.S., Miles, M., Du, L., Koyama, T., Meier, E.R., et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 168 (2015), 291–300.
13. Yazdanbakhsh, K., Ware, R.E., Noizat-Pirenne, F., Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 120 (2012), 528–537.
14. Vingert, B., Tamagne, M., Habibi, A., Pakdaman, S., Ripa, J., Elayeb, R., et al. Phenotypic differences of CD4+ T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol 45 (2015), 1868–1879.
15. Bao, W., Zhong, H., Manwani, D., Vasovic, L., Uehlinger, J., Lee, M.T., et al. Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease. Am J Hematol 88 (2013), 736–740.
16. Sippert, E.Â., Visentainer, J.E., Alves, H.V., Rodrigues, C., Gilli, S.C., Addas-Carvalho, M., et al. Red blood cell alloimmunization in patients with sickle cell disease: correlation with HLA and cytokine gene polymorphisms. Transfusion 57 (2017), 379–389.
17. Noizat-Pirenne, F., Habibi, A., Mekontso-Dessap, A., Razazi, K., Chadebech, P., Mahevas, M., et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang 108 (2015), 262–267.
18. Noizat-Pirenne, F., Tournamille, C., Relevance of RH variants in transfusion of sickle cell patients. Transfus Clin Biol 18 (2011), 527–535.
19. Flegel, W.A., von Zabern, I., Doescher, A., Wagner, F.F., Strathmann, K.P., Geisen, C., et al. D variants at the RhD vestibule in the weak D type 4 and Eurasian D clusters. Transfusion 49 (2009), 1059–1069.
20. Casas, J., Friedman, D.F., Jackson, T., Vege, S., Westhoff, C.M., Chou, S.T., Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 55 (2015), 1388–1393.
21. Mekontso Dessap, A., Pirenne, F., Razazi, K., Moutereau, S., Abid, S., Brun-Buisson, C., et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol 91 (2016), 1181–1184.
22. Gardner, K., Hoppe, C., Mijovic, A., Thein, S.L., How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol 170 (2015), 745–756.
23. de Montalembert, M., Dumont, M.D., Heilbronner, C., Brousse, V., Charrara, O., Pellegrino, B., et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 96 (2011), 801–807.
24. Dumas, G., Habibi, A., Onimus, T., Merle, J.C., Razazi, K., Mekontso Dessap, A., et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 127 (2016), 1062–1064.
25. Hayes, C., Shafi, H., Mason, H., Klapper, E., Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report. Transfus Apher Sci 54 (2016), 253–255.